Stockscreener 앱 받기
33.12
13.23%
3.87
시간 외 거래:
33.66
0.54
+1.63%
전일 마감가:
$29.25
열려 있는:
$29.43
하루 거래량:
4.24M
Relative Volume:
3.67
시가총액:
$2.20B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-12.13
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
+117.61%
1개월 성능:
+154.18%
6개월 성능:
+233.87%
1년 성능:
+180.20%
1일 변동 폭
$29.13
$33.50
1주일 범위
$14.94
$33.50
52주 변동 폭
$8.241
$33.50
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
33.12 | 1.91B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Will Mineralys Therapeutics Inc. benefit from AI trendsJuly 2025 Weekly Recap & Daily Stock Trend Reports - khodrobank.com
Mineralys Therapeutics Announces Public Offering of Shares - TipRanks
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys: Soaring As Rival's Hypertension Data Falls ShortBuy The Next Dip (MLYS) - Seeking Alpha
Stock Market Update: Bruker, Mineralys Therapeutics, and Other Big Stocks Moving Lower in Wednesday's Pre-Market Session - AInvest
Can volume confirm reversal in Mineralys Therapeutics Inc.Product Launch & Accurate Buy Signal Alerts - Newser
Mineralys In The Money As Lorundrostat Gets Close To Market - insights.citeline.com
Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Short interest data insights for Mineralys Therapeutics Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Latham Advises Mineralys Therapeutics on Upsized US$250 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
How to interpret RSI for Mineralys Therapeutics Inc. stockM&A Rumor & Risk Managed Investment Entry Signals - Newser
Institutional scanner results for Mineralys Therapeutics Inc.Portfolio Return Report & Long-Term Growth Plans - Newser
Can Mineralys Therapeutics Inc. disrupt its industryGold Moves & Growth Focused Entry Point Reports - khodrobank.com
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Identifying reversal signals in Mineralys Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 - Investing.com
Will Mineralys Therapeutics Inc. announce a stock splitPortfolio Gains Summary & Technical Pattern Recognition Alerts - khodrobank.com
Mineralys Therapeutics shares fall 6.38% premarket after suspending prospectus supplement for ATM equity offering. - AInvest
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter
Order flow analysis tools used on Mineralys Therapeutics Inc.Weekly Market Outlook & Stepwise Trade Signal Implementation - Newser
What high frequency data says about Mineralys Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Mineralys Therapeutics Prices $250 Million Notes Offering - MarketScreener
Mineralys Therapeutics stock hits all-time high at 22.0 USD By Investing.com - Investing.com Canada
What MACD and RSI say about Mineralys Therapeutics Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
How sentiment analysis helps forecast Mineralys Therapeutics Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Published on: 2025-09-03 02:21:26 - Newser
How moving averages guide Mineralys Therapeutics Inc. tradingEarnings Overview Report & Safe Entry Point Identification - Newser
Key metrics from Mineralys Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Stepwise Trade Execution Plans - Newser
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Quarterly Market Summary & Daily Price Action Insights - Newser
Using RSI to spot recovery in Mineralys Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Mineralys Therapeutics' $250M Upsized Equity Raise: A Strategic Inflection Point for Hypertension Innovation - AInvest
Published on: 2025-09-03 00:47:22 - Newser
Published on: 2025-09-03 00:45:39 - Newser
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale - Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr - Nasdaq
Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million - Quiver Quantitative
Mineralys Therapeutics announces pricing of upsized $250.0 million underwritten public offering of common stock - MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Does Mineralys Therapeutics Inc. align with a passive investing strategyQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Mineralys Stock Surges 86.43% on $0.43B Trading Volume Ranked 256th in Market Activity as $175M Public Offering Drives Institutional Confidence - AInvest
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
AstraZeneca's Blood Pressure Drug Baxdrostat Shows Positive Trial Results, Boosting Mineralys Therapeutics Shares by 85% - AInvest
Mineralys Therapeutics announces proposed public offering of common stock - MarketScreener
Mineralys Therapeutics Halts Common Stock Offering - TipRanks
Mineralys Therapeutics down on $175 mln stock offering plans - TradingView
Is Mineralys Therapeutics Inc. reversing from oversold territory2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Mineralys Therapeutics launches $175 million public stock offering - Investing.com
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Aug 13 '25 |
Sale |
12.93 |
11,365 |
146,987 |
92,891 |
1.75%
1.11%
자본화:
|
볼륨(24시간):